首页> 外文期刊>Infectious disorders drug targets >Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic Review of Existing Literature and Transmission Modelling of Seroprevalence Studies
【24h】

Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic Review of Existing Literature and Transmission Modelling of Seroprevalence Studies

机译:Burden of Congenital Rubella Syndrome (CRS) in Bangladesh: Systematic Review of Existing Literature and Transmission Modelling of Seroprevalence Studies

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Objectives: Congenital Rubella Syndrome (CRS) is the leading causeof vaccine-preventable congenital anomalies. Comprehensive country-level data on the burden ofCRS in low and middle-income countries, such as Bangladesh, are scarce. This information is essentialfor assessing the impact of rubella vaccination programs. We aim to systematically reviewthe literature on the epidemiology of CRS and estimate the burden of CRS in Bangladesh.Methods: We conducted a systematic review of existing literature and transmission modelling ofseroprevalence studies to estimate the pre-vaccine period burden of CRS in Bangladesh. OVIDMedline (1948 – 23 November 2016) and OVID EMBASE (1974 – 23 November 2016) weresearched using a combination of the database-specific controlled vocabulary and free text terms.We used an age-stratified deterministic model to estimate the pre-vaccination burden of CRS inBangladesh.Findings: Ten articles were identified, published between 2000 and 2014, including seven crosssectionalstudies, two case series and one analytical case-control study. Rubella seropositivityranged from 47.0% to 86.0% among all age population. Rubella sero–positivity increased withage. Rubella seropositivity among women of childbearing age was 81.0% overall. The estimatedincidence of CRS was 0·99 per 1,000 live births, which corresponds to approximately 3,292 CRScases annually in Bangladesh.Conclusion: The estimated burden of CRS in Bangladesh during the pre-vaccination period washigh. This will provide important baseline information to assess the impact and cost-effectivenessof routine rubella immunisation, introduced in 2012 in Bangladesh.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号